Insmed reported $29.34M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
BioMarin Pharmaceutical USD 154.94M 3.38M Jun/2025
Cytokinetics 112.55M 12.71M Jun/2025
Dynavax Technologies USD 14.04M 13.5M Jun/2025
Gilead Sciences USD 1.5B 39M Jun/2025
Insmed USD 29.34M 8.06M Jun/2025
Novartis USD 3.32B 5M Jun/2025
Regeneron Pharmaceuticals USD 530.2M 264.7M Jun/2025
Sarepta Therapeutics USD 153.22M 15.66M Jun/2025
Ultragenyx Pharmaceutical USD 23M 5.66M Jun/2025
Vertex Pharmaceuticals USD 407.5M 44.5M Jun/2025